This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Cystic fibrosis
  • /
  • Vitamin E status and its determinants in patients ...
Journal

Vitamin E status and its determinants in patients with cystic fibrosis.

Read time: 1 mins
Published:1st Sep 2018
Author: Sapiejka E, Krzy?anowska-Jankowska P, Wenska-Chy?y E, Szczepanik M, Walkowiak D, Cofta S et al.
Availability: Pay for access, or by subscription
Ref.:Adv Med Sci. 2018;63(2):341-346.
DOI:10.1016/j.advms.2018.04.001

Purpose: The risk of vitamin E deficiency is of primary concern in cystic fibrosis patients. However, early diagnosis and routine vitamin E supplementation can lead to its normal or even high levels. In the present study, we assessed vitamin E status in a large group of cystic fibrosis patients. Moreover, we also aimed to establish determinants of its body resources in cystic fibrosis patients.

Material and methods: The study group comprised 211 cystic fibrosis patients aged from 1 month to 48 years. In all of them serum α-tocopherol concentration was analyzed using high-performance liquid chromatography.

Results: Median vitamin E concentration was 9.9 μg/ml (1st–3rd quartile: 7.5–13.5). Vitamin E deficiency was found in 17 (8.0%) and high levels were documented in 24 (11.4%) participants. Patients with and without vitamin E deficiency did not differ significantly with respect to age, standardized body weight and height, FEV1, albumin concentration and vitamin E supplementation dose. However, vitamin E deficiency appeared more frequently in participants without vitamin E supplementation. Moreover, in multiple linear regression analysis pancreatic insufficiency, severe CFTR gene mutation and vitamin E dose, were potentially defined as determinants of vitamin E concentration.

Conclusions: Vitamin E deficiency in cystic fibrosis patients is rather rare nowadays. Excessive vitamin E levels seem to be more frequent. Vitamin E status wasn’t documented to be strictly related to clinical determinants. Beyond vitamin E supplementation, exocrine pancreatic function and CFTR gene mutations may have had an impact on the vitamin E body resources in cystic fibrosis patients.

Read abstract on library site

Access full article